Scottish HTA Nod For Keytruda In Endometrial Carcinoma Marks UK First
Executive Summary
Scotland has approved reimbursement for MSD’s Keytruda in combination with Eisai’s Lenvima for endometrial carcinoma. Meanwhile, a recommendation in England has been delayed.
You may also be interested in...
Scotland Says No To Novartis’ Piqray
Scotland’s health technology assessment body, the SMC, has rejected Novartis’ targeted breast cancer drug Piqray, but accepted Lilly’s Verzenio, also for breast cancer.
Keytruda: NICE Rejects English Funding For Endometrial Cancer But Says Yes For Renal Cancer
NICE has preliminarily rejected MSD’s drug for endometrial cancer in a decision that contrasts with that of its health technology assessment counterpart in Scotland.
England Okays Funding For Revestive, Jyseleca & Fintepla
England’s health technology appraisal body NICE has recommended Galapagos’ Jyseleca for ulcerative colitis, Takeda’s Revestive for short bowel syndrome and Zogenix’s Fintepla for seizures associated with Dravet syndrome.